

Contents

EDITORIAL

Editor-in-Chief's Introduction

Andrew J. Dowson

1-2

KEYNOTE ADDRESS

The Evolution of Headache Management in Primary Care

Robert Smith

3-6

REVIEW

New Initiatives for the Management of Headache in Primary Care: Review of the Second Annual Meeting of the Headache Care for Practising Clinicians (HCPC)

Andrew J. Dowson, Stewart J. Tepper and Roger K. Cady

7-13

POSTERS

ID Migraine: Development and Validation of a Three-item, Self-administered Questionnaire to Identify Migraine Sufferers in a Primary Care Population

S. Rasmussen, R. B. Lipton, J. Hettiarachchi and C. Sikes

14-16

Ominous Headache in Primary Care: Myth or Reality?

David Watson

17-18

A Multinational Study of Migraine Treatment Patterns Among Young, Active Women: The Migraine Effect on Life and Treatment (MELT) Study

Aud Nome Dueland, Rogelio Leira, Joris De Vries and Susan Bolge

19-21

Patients' Attitudes to Migraine: Its Prevalence, Impact and Treatment. The MAZE Study, Phases I and II

E. Anne MacGregor, Jan Brandes and Astrid Eikermann

22-25

Impact of Migraine on Sufferers and their Families. The MAZE Study, Phase III

E. Anne MacGregor, Jan Brandes, Astrid Eikermann and Rose Giammarco

26-29

Patients' Migraine Management Strategies: Interim Results of an On-line Market Research Study: MAZE Study Phase IV

E. Anne MacGregor, Jan Brandes, Astrid Eikermann and Rose Giammarco

30-32

Usefulness of a Disability Diary to Facilitate Communication Between Migraine Patients and Primary Care Physicians in Assessing Symptoms, Migraine-related Disability and Medication Effectiveness. The I-MAX Migraine Disability Assessment Program, Spain

V. Baos, M. Torrecilla, A. Serrano, M. T. Caloto, G. Nocea and W. C. Gerth on Behalf of the I-MAX Study Group

33-38

Measuring the Impact Migraine Has on the Patient Can Help to Determine an Appropriate Treatment Strategy: Physicians' Assessment

R. B. Lipton, W. F. Holmes, J. P. Sawyer, P. Blakeborough and W. F. Stewart

39-42

Efficacy and Tolerability of Eletriptan vs. Sumatriptan 100mg for the Acute Treatment of Migraine

J. Hettiarachchi, S. Rasmussen, C. Sikes and W. Sun

43-45

Improved 24-Hour Migraine Quality of Life with Rizatriptan 10mg compared to Non-Triptan Treatment. I-MAX Migraine Disability Assessment Program, Spain

W. C. Gerth, C. Bertral, F. Ester, A. Castellanos, M. T. Caloto and G. Nocea on Behalf of the I-MAX Study Group

46-49

Improved Migraine Treatment Outcomes with Rizatriptan 10mg Compared to Non-triptan Treatment. I-MAX Migraine Disability Assessment Program, Spain

M. Torrecilla, M. T. Caloto, G. Nocea and W. C. Gerth on Behalf of the I-MAX Study Group

50-54

Evaluation of Sumatriptan 50 mg and 100 mg Tablets Administered During the Mild Pain Phase of a Menstrually Associated Migraine Attack	
<i>N. Savani, Diane Boswell and Jane Loftus</i>	55-56
A Prospective Randomized Comparison of Early vs. Late Intervention During a Migraine Attack: Early Intervention Increases the Efficacy of Sumatriptan	
<i>Joachim Scholpp, Ruediger Schellenberg, Beate Moeckesch and Norbert Banik</i>	57-59
Efficacy of a New Formulation of Sumatriptan Tablets when Administered Early in a Migraine Attack	
<i>Hans Carpay, Giorgio Cruccu, Diane Boswell, Frances Kinrade and Martin Jones</i>	60-62
Ability to Function Following Treatment with a New Formulation of Sumatriptan Tablets	
<i>Giorgio Cruccu, Hans Carpay, Jackie Kwong, Diane Boswell and Claire Alderton</i>	63-65
Long-term Use of Sumatriptan Nasal Spray is Well-tolerated in Adolescent Migraineurs	
<i>Andrew Dowson, Laura Lisk, Christopher Webster and Mary S. Richardson</i>	66-68
Treatment of Migraine in Adolescents: A Review of Efficacy Data with Sumatriptan Nasal Spray	
<i>Mirja Hämäläinen, Christopher Webster, Laura Lisk and Martin Jones</i>	69-71
Zolmitriptan Formulations Provide Fast Relief in the Acute Treatment of Migraine	
<i>Bruce Charlesworth and Roger Yates</i>	72-74
Patients Who Treat their Migraine with Zolmitriptan while the Pain is Still Mild Experience Improved Efficacy	
<i>Christian Lucas, Jack A. Klapper, Øyvind Røsjo, Anne Poole Jørgensen, Thierry Soisson and Bruce Charlesworth</i>	75-77
Zolmitriptan Orally Disintegrating Tablet (ODT) is a Highly Effective Migraine Therapy that Patients Prefer Over Other Commonly Used Treatments	
<i>Andrew Dowson and Bruce Charlesworth</i>	78-80
Zolmitriptan Nasal Spray Demonstrates Fast, Reliable Efficacy in the Acute Treatment of Migraine	
<i>Bruce R. Charlesworth</i>	81-84
Zolmitriptan Nasal Spray Improves Patient Satisfaction by Providing Fast and Effective Relief from Migraine Symptoms	
<i>Carl Dahlöf, Steen Boes-Hansen and Andrew Dowson</i>	85-87
Instructions to Authors	I-III